Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Medifast, Inc.NYSE: MED
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.19, compared with -$0.07 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.83.
Context
- EPS (Diluted) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$0.86 (+49.4%) for the fiscal year ending Dec 2026, a step up from the -994.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.19+88.5% QoQ
- Last fiscal yearDec 2025
- -$1.7-994.7% YoY
- LTMMar 2026
- -$1.83-181.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -171.4% | -395.5% | -224.0 pp |
| 1 year | -994.7% | +49.4% | +1044.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.70) USD
- Year-over-year change
- -994.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.70) | -994.7% |
| FY2024 | 2024-12-31 | 0.19 | -97.9% |
| FY2023 | 2023-12-31 | 9.10 | -28.5% |
| FY2022 | 2022-12-31 | 12.73 | -8.4% |
| FY2021 | 2021-12-31 | 13.89 | — |
EPS (Diluted) vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -181.5% is the 9th highest of 10, against a peer median of +10.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jan 2026 | $3.72 USD | -37.1% | — | |
| LTM Dec 2025 | $1.42 USD | +43.4% | +27.2% | |
| LTM Feb 2026 | $0.62 USD | +83.0% | -36.2% | |
| FY2025 | HK$0 HKD | -100.0% | — | |
| LTM May 2026 | -$0.13 USD | -233.6% | — | |
| LTM Mar 2026 | -$0.31 USD | +43.9% | — | |
| LTM Mar 2026 | -$1.16 USD | +43.9% | — | |
| LTM Mar 2026 | -$1.83 USD | -181.5% | — | |
| LTM Mar 2026 | -$2.81 USD | -17.6% | — | |
AIIORobo.ai Inc. | FY2025 | -$10.59 USD | +10.3% | — |
| Peer median (excluding MED) | — | +10.3% | -4.5% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.